| | |
Page
|
| |||
| | | | 2 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 11 | | | |
| | | | 13 | | | |
| | | | 19 | | | |
| | | | 23 | | | |
| | | | 30 | | | |
| | | | 32 | | | |
| | | | 35 | | | |
| | | | 36 | | | |
| | | | 37 | | |
Name
|
| |
Positions and Offices Held with Axcella
|
| |
Director Since
|
| |
Age
|
|
Gary Pisano, Ph.D. | | |
Director
|
| |
2011
|
| |
59
|
|
Grégory Behar | | |
Director
|
| |
2016
|
| |
51
|
|
Cristina M. Rondinone, Ph.D. | | |
Director
|
| |
2018
|
| |
60
|
|
Shreeram Aradhye, M.D. | | |
Director
|
| |
2020
|
| |
58
|
|
Name
|
| |
Positions and Offices Held with Axcella
|
| |
Director
Since |
| |
Class and Year
in Which Term Will Expire |
| |
Age
|
|
David R. Epstein | | | Director | | |
2017
|
| |
Class I – 2023
|
| |
59
|
|
William D. Baird III | | | Director | | |
2018
|
| |
Class I – 2023
|
| |
49
|
|
William Hinshaw | | |
Director, Chief Executive Officer
|
| |
2018
|
| |
Class III – 2022
|
| |
52
|
|
Stephen Hoge, M.D. | | | Director | | |
2014
|
| |
Class III – 2022
|
| |
45
|
|
Catherine A. Sohn, PharmD. | | | Director | | |
2019
|
| |
Class III – 2022
|
| |
68
|
|
Name
|
| |
Position Held with Axcella
|
| |
Officer
Since |
| |
Age
|
|
Manu Chakravarthy, M.D., Ph.D.(1) | | |
Executive Vice President of Clinical Development, Chief Medical Officer
|
| |
2017
|
| |
47
|
|
Paul Fehlner, J.D., Ph.D. | | |
Senior Vice President, Chief Legal Officer and Corporate Secretary
|
| |
2018
|
| |
57
|
|
Laurent Chardonnet | | | Senior Vice President, Chief Financial Officer | | |
2019
|
| |
56
|
|
Alison Schecter, M.D.(1) | | | President of Research and Development | | |
2021
|
| |
57
|
|
| | |
2020
|
| |
2019
|
| ||||||
Audit fees(1)
|
| | | $ | 380,320 | | | | | $ | 355,250 | | |
Audit-related fees(2)
|
| | | | 205,461 | | | | | | 436,424 | | |
Tax fees
|
| | | | — | | | | | | — | | |
All other fees(3)
|
| | | | 1,895 | | | | | | 1,895 | | |
Total fees
|
| | | $ | 587,676 | | | | | $ | 793,569 | | |
Name
|
| |
Fees Paid
In Cash ($) |
| |
Option
Awards ($)(1) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||
Shreeram Aradhye, M.D.
|
| | | | 11,667 | | | | | | 69,335 | | | | | | 314,858(2) | | | | | | 395,860 | | |
William D. Baird III
|
| | | | 62,500 | | | | | | 28,891 | | | | | | — | | | | | | 91,391 | | |
Grégory Behar
|
| | | | 42,500 | | | | | | 28,891 | | | | | | — | | | | | | 71,391 | | |
David R. Epstein
|
| | | | 150,000(3) | | | | | | 275,747 | | | | | | 300,000(4) | | | | | | 725,747 | | |
Stephen Hoge, M.D.
|
| | | | 45,852 | | | | | | 28,891 | | | | | | — | | | | | | 74,743 | | |
Gary Pisano, Ph.D.
|
| | | | 42,500 | | | | | | 28,891 | | | | | | — | | | | | | 71,391 | | |
Cristina M. Rondinone, Ph.D.
|
| | | | 39,000 | | | | | | 28,891 | | | | | | — | | | | | | 67,891 | | |
Catherine A. Sohn, PharmD.
|
| | | | 47,750 | | | | | | 28,891 | | | | | | — | | | | | | 76,641 | | |
| | |
Option Awards(1)
|
| |||||||||
Directors
|
| |
Exercisable
(#) |
| |
Unexercisable
(#) |
| ||||||
Shreeram Aradhye, M.D.
|
| | | | 1,833 | | | | | | 20,167 | | |
William D. Baird III
|
| | | | 42,891 | | | | | | 30,140 | | |
Grégory Behar
|
| | | | 11,000 | | | | | | 11,000 | | |
David R. Epstein(2)
|
| | | | 771,682 | | | | | | 228,764 | | |
Stephen Hoge, M.D.
|
| | | | 65,288 | | | | | | 11,000 | | |
Gary Pisano, Ph.D.
|
| | | | 92,433 | | | | | | 11,000 | | |
Cristina M. Rondinone, Ph.D.
|
| | | | 39,834 | | | | | | 28,310 | | |
Catherine A. Sohn, PharmD.
|
| | | | 9,165 | | | | | | 23,835 | | |
| | |
Annual
Retainer |
| |||
Board of Directors: | | | | | | | |
All non-employee members, except chairman
|
| | | $ | 35,000 | | |
Audit Committee: | | | | | | | |
Members
|
| | | $ | 7,500 | | |
Chairman
|
| | | $ | 15,000 | | |
Compensation Committee: | | | | | | | |
Members
|
| | | $ | 5,000 | | |
Chairman
|
| | | $ | 10,000 | | |
Nominating and Corporate Governance Committee: | | | | | | | |
Members
|
| | | $ | 4,000 | | |
Chairman
|
| | | $ | 8,000 | | |
Plan Category
|
| |
Number of
Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (#) |
| |
Weighted-average
Exercise Price of Outstanding Options, Warrants and Rights ($) |
| |
Number of Securities
Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in First Column) (#) |
| |||||||||
Equity compensation plans approved by security holders(1)
|
| | | | 5,267,547(2) | | | | | $ | 5.95 | | | | | | 1,365,174(3)(4) | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 5,267,547 | | | | | $ | 5.95 | | | | | | 1,365,174 | | |
Name
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Stock
Awards ($)(1) |
| |
Option
Awards ($)(1) |
| |
Non-Equity
Incentive Plan Compensation ($)(2) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||||||||||||||
William Hinshaw
President and CEO |
| | | | 2020 | | | | | | 517,500 | | | | | | — | | | | | | 703,500 (3) | | | | | | 418,531 | | | | | | 286,000 | | | | | | 8,550(4) | | | | | | 1,934,081 | | |
| | | 2019 | | | | | | 496,731 | | | | | | — | | | | | | — | | | | | | 560,049 | | | | | | 288,750 | | | | | | — | | | | | | 1,345,530 | | | ||
Laurent Chardonnet
Senior Vice President and Chief Financial Officer |
| | | | 2020 | | | | | | 375,000 | | | | | | — | | | | | | — | | | | | | 55,509(5) | | | | | | 151,875 | | | | | | 49,189(6) | | | | | | 631,573 | | |
| | | 2019 | | | | | | 38,462 | | | | | | — | | | | | | — | | | | | | 160,977(5) | | | | | | — | | | | | | 3,000(7) | | | | | | 202,439 | | | ||
Manu Chakravarthy, M.D., Ph.D.(9)
Executive Vice President of Clinical Development, Chief Medical Officer |
| | | | 2020 | | | | | | 415,392 | | | | | | 300,000(8) | | | | | | 298,800 | | | | | | — | | | | | | 167,219 | | | | | | 8,550(4) | | | | | | 1,189,961 | | |
| | | 2019 | | | | | | 374,000 | | | | | | — | | | | | | — | | | | | | 1,180,679 | | | | | | 155,210 | | | | | | — | | | | | | 1,709,889 | | |
Name
|
| |
Target Bonus
(% of base salary) |
| |||
William Hinshaw
|
| | | | 55 | | |
Laurent Chardonnet
|
| | | | 40 | | |
Manu Chakravarthy, M.D., Ph.D.(1)
|
| | | | 40 | | |
| | | | | | | | | | | | | | |
Option awards
|
| |
Stock awards
|
| ||||||||||||||||||||||||||||||||||||
Name
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units Not Vested (#) |
| |
Market
value of shares or units of stock that have not vested ($)(1) |
| |
Equity
Incentive Plan Awards: Number of Unearned Share Units or Other Rights That Have Not Vested (#) |
| |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that Have not Vested ($)(1) |
| | ||||||||||||||||||||||||||
William Hinshaw
President and CEO |
| | | | 645,580(2) | | | | | | 293,448(2) | | | | | | — | | | | | | 6.21 | | | |
6/21/2028
|
| | | | 50,000(5) | | | | | | 259,500 | | | | | | — | | | | | | — | | | | ||
| | | 26,600(3) | | | | | | 34,200(3) | | | | | | — | | | | | | 13.83 | | | |
3/22/2029
|
| | | | — | | | | | | — | | | | | | 150,000(6) | | | | | | 778,500 | | | | ||||
| | | —(4) | | | | | | 156,700(4) | | | | | | — | | | | | | 4.12 | | | |
1/2/2030
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||||
Laurent Chardonnet
Senior Vice President and Chief Financial Officer |
| | | | 18,125(7) | | | | | | 54,375(7) | | | | | | — | | | | | | 3.40 | | | |
12/18/2029
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||
| | | 6,250(8) | | | | | | 18,750(8) | | | | | | — | | | | | | 3.40 | | | |
12/18/2029
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||||
| | | — | | | | | | — | | | | | | 25,000(9) | | | | | | 3.40 | | | |
12/18/2029
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||||
Manu Chakravarthy, M.D., Ph.D.(13)
Executive Vice President of Clinical Development, Chief Medical Officer |
| | | | 161,030(10) | | | | | | 23,013(10) | | | | | | — | | | | | | 6.52 | | | |
8/9/2027
|
| | | | 60,000(12) | | | | | | 311,400 | | | | | | — | | | | | | — | | | | ||
| | | 58,899(11) | | | | | | 58,907(11) | | | | | | — | | | | | | 13.83 | | | |
3/11/2029
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | ||||
| | | 10,250(7) | | | | | | 30,750(7) | | | | | | — | | | | | | 3.40 | | | |
12/18/2029
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | |
| | |
Shares beneficially owned
|
| |||||||||
Name of Beneficial Owner
|
| |
Number
|
| |
Percentage
|
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
Flagship Pioneering(1)
|
| | | | 12,548,414 | | | | | | 33.3% | | |
FMR LLC(2)
|
| | | | 5,631,132 | | | | | | 14.9% | | |
Nestlé S.A.(3) | | | | | 4,305,541 | | | | | | 11.4% | | |
HarbourVest Partners, LLC(4)
|
| | | | 2,807,981 | | | | | | 7.5% | | |
Named executive officers and directors: | | | | | | | | | | | | | |
William Hinshaw(5)
|
| | | | 783,638 | | | | | | 2.1% | | |
Manu Chakravarthy, M.D., Ph.D.(6)
|
| | | | 271,707 | | | | | | * | | |
Laurent Chardonnet(7)
|
| | | | 41,422 | | | | | | * | | |
David R. Epstein(8)
|
| | | | 994,870 | | | | | | 2.6% | | |
Gary Pisano, Ph.D.(9)
|
| | | | 103,433 | | | | | | * | | |
Stephen Hoge, M.D.(10)
|
| | | | 76,288 | | | | | | * | | |
William D. Baird III(11)
|
| | | | 57,080 | | | | | | * | | |
Cristina M. Rondinone, Ph.D.(12)
|
| | | | 53,717 | | | | | | * | | |
Catherine A. Sohn, PharmD.(13)
|
| | | | 24,831 | | | | | | * | | |
Grégory Behar, M.B.A.(14)
|
| | | | 22,000 | | | | | | * | | |
Shreeram Aradhye, M.D.(15)
|
| | | | 3,667 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(16)
|
| | | | 2,511,647 | | | | | | 6.7% | | |